Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its Oncologic Drugs Advisory Committee at a Dec. 2 meeting whether the thyroid cancer drug should be limited to only those patients with progressive, symptomatic disease and if post-marketing studies are needed to determine the optimal dose.
You may also be interested in...
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.